ABSTRAm. The ability of synthetic metalloporphyrins to suppress heme oxygenase activity and bilirubin formation has recently become of considerable clinical and experimental interest for suppression of jaundice in humans, including neonatal hyperbilirubinemia. The present investigation compares the biochemical effects of Sn-and Znprotoporphyrins on the predominant heme oxygenase isozyme present in the brain (HO-2) at activity, protein, and transcript levels and describes the ability of Sn-protoporphyrin to adversely affect this isozyme. Specifically, 6 h after a modest dose (50 pmollkg, i.v.) of Sn-protoporphyrin, heme oxygenase activity in rat brain was nearly undetectable. In addition, as revealed by Western blot analysis, HO-2 protein level was decreased by 20% and the electrophoretic behavior of the protein in the microsoma1 membranes was altered. Moreover, the activity of NADPH-cytochrome P-450 reductase, which is required for the oxidation of heme molecule, was markedly decreased (60% of control). Western immunoblot analysis revealed also a pronounced decrease in the reductase protein level. The inducible form of heme oxygenase, HO-1, was not detectable by immunoblotting in brain microsomes of either control or Sn-protoporphyrin-treated animals. Northern blot analyses did not reveal decreases in the levels of the single HO-1 mRNA (1.8 kb) or the two HO-2 transcripts (1.3 and 1.9 kb), suggesting that Sn-protoporphyrin mediates its effects on heme oxygenase isozymes at the protein level. Zn-protoporphyrin, on the other hand, had no deleterious effect on brain parameters presently investigated. The data suggest that Sn-protoporphyrin exerts its inhibitory effects on heme oxygenase activity in the brain through multiple mechanisms involving direct effect on HO-2 protein and its cellular level, inhibiting NADPHcytochrome P-450 reductase activity, decreasing the cellular content of the reductase, as well as inhibiting heme oxygenase activity by serving as a competitive inhibitor. We suggest that Zn-protoporphyrin may be the safer alternative if metalloporphyrins are to be used to control hyperbilirubinemia. (Pediatr Res 32: 324-329,1992) Abbreviations HO-1 and HO-2, isoforms of heme oxygenase Received February 13, 1992; accepted April 28, 1992. Corresvondence and re~rint reauests: Mahin D. Maines, University of Rochester School of' Medicine, ~e i a r t m e n i of Biophysics, 601 Elmwood ~v e . , Rochester, NY 14642.
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The cleavage of heme molecule to form open tetrapyrrole biliverdin is the first and rate limiting step in the formation of bile pigments and is catalyzed by the concerted activity of the microsomal enzymes, heme oxygenase and NADPH cytochrome P-450 reductase (1, 2) . Heme b (hemin, heme, Fe-protoporphyrin-IX), which constitutes the prosthetic moiety of b type cytochromes and Hb, is the physiologic substrate of heme oxygenase (3, 4) . Synthetic metalloporphyrins including Sn-and Znprotoporphyrins, however, are also capable of binding to the active site of the enzyme (5, 6) but are poor substrates and, unlike heme, do not undergo oxidative degradation by heme oxygenase (7, 8) . In fact, because of its seemingly potent ability to decrease bile pigment formation and serum bilirubin levels by competitive inhibition of heme oxygenase, Sn-protoporphyrin has been used therapeutically to control hyperbilirubinemia in humans, including neonates (9-1 1).
The ability of metalloporphyrins to generate active oxygen species renders them highly reactive complexes capable of mediating the destruction of macromolecules (12) (13) (14) (15) (16) (17) (18) (19) . Not only has Sn-protoporphyrin been shown to degrade bilirubin via oxygen radical formation (1 6-18) , but the complex plus photo-irradiation has been shown to promote lipid peroxidation both in vivo and in vitro (20) . In addition, recent studies in this laboratory have demonstrated that Sn-protoporphyrin causes marked perturbations in adrenal and testicular cytochrome P-450-dependent steroidogenesis along with decreases in cytochrome P-450 levels (21) . These modulations have been suggested to be a manifestation of the ability of Sn-protoporphyrin to generate free radicals ,m . \ VI).
There exist two isoforms of heme oxygenase, HO-1 and HO-2 (22,23), with each being a different gene product (24, 25) . The HO-1 isozyme, which has also been designated a heat shock protein, HSP-32 (26) (27) (28) (29) , is by far the more stable form. This is exemplified by the observation that upon exposure of isozymes to 65°C for 10 min, 70% of HO-1 activity is maintained, whereas HO-2 activity decreases by 80% (22) . The resilient nature of HO-1 could in part reflect the difference between the isozymes in their primary and secondary structures (22) (23) (24) (25) 30) or alternatively may reflect a differential mode of association of the two isozymes with endoplasmic reticulum membranes. For instance, HO-2 may be localized in the microsomes in such a way that it is more accessible to cellular milieu and thus more susceptible to cytotoxic insult. In addition, the two forms differ in their regulation; the exquisite sensitivity of HO-1 production to an array of stimuli has been extensively documented (reviewed in Ref. 4 ), whereas HO-2 production appears to be refractory to exogenous agents (4, 23) . Normally, HO-2 is the more prevalent species in most tissues; this is especially true in the brain, where HO-2 is the only form detectable by immunoblotting (29, (31) (32) (33) . It is noteworthy that the existence of HO-2 was uncovered only rather recently (22) , and therefore many of the earlier studies on metalloporphyrin-mediated inhibition of bilirubin formation Sn-PROTOPORPHYRIN EFFECTS ON HO-2 325 were conducted before such knowledge. The results of those Corp., Cleveland, OH). The probes were further purified by spin studies were interpreted accordingly, as if tissues only contained column chromatography as described by Maniatis et al. (42) , HO-1.
using Sephadex G-50. Sn-protoporphyrin reportedly can cross the blood-brain barrier Total RNA was isolated from rat brain by the guanidine and gain entry to neuronal tissue (34, 3 9 , where, as noted above, isothiocyanate/cesium chloride technique, as described by Chirgvirtually all of the heme oxygenase is 1-10-2. Accordingly, the win et al. (43) . Poly(A)+ RNA was isolated using oligo(dT)-present investigation was undertaken to examine the effect in cellulose columns (44) . Subsequently, 4 pg of poly (A)+ RNA vivo of Sn-protoporphyrin on brain levels of HO-2 protein and were fractionated on a denaturing formaldehyde-agarose (1.2%) its transcripts (1.3 and 1.9 kb) as well as the heme degrading gel and transferred to Nytran (44) . Prehybridization, hybridizaactivity of this enzyme. The effect of Sn-protoporphyrin on other tion of the appropriately labeled cDNA probe, posthybridization microsomal constituents, including NADPH cytochrome P-450 washes of the filters, and autoradiography on Kodak XOMATreductase, HO-1 protein, and mRNA (1.8 kb), was also investi-AR film at -80°C were performed as previously described (33) . gated, and actions of the tin complex were compared with those Northern blots were quantified densitometrically using an Ultra of Zn-protoporphyrin. We have uncovered deleterious effects of Scan XL densitometer (Pharmacia LKB Biotechnology, Inc., Sn-protoporphyrin on HO-2 protein and activity and found the Piscataway, NJ). effects not to be specific to the heme oxygenase isozyme, but to
Assays. Microsomal heme oxygenase activity was measured in extend to NADPH-cytochrome P-450 reductase as well.
both the presence and absence of exogenous NADPH-cytochrome P-450 reductase, as detailed elsewhere (39) . Purified rat MATERIALS AND METHODS liver biliverdin reductase was used to convert biliverdin to bilirubin, and the amount of bilirubin formed was determined using Materja/s, Cofactors and chromatographic media were ob-an extinction coefficient of 40 mM-lcm-l between 470 and 530 tained from Sigma Chemical ~0 .
(St. Louis, ~0 ) . sn-protopor-nm (2). NADPH-cytochrome P-450 reductase activity was estiphyrin-IX dichloride and Zn-protoporphyrin-IX were obtained mated as dwxibed by Strobel and Dignam (45) by measuring from Porphyrin Products (Logan, UT). Goat antirabbit the increase in absorbance at 550 nm as a result of the reduction horseradish perioxidase conjugate and normal goat serum were of cytochrome c in the Presence of N4DPH. purchased from Organon Teknika-Cappel (Durham, NC) and
The protein concentration was determined by the method of Gibco-BRL (Grand Island, NY), respectively. Nytran sheets and Lowry et (46) using BSA as the protein stzindard. nitrocellulose transfer membrane, with a pore size of 0.2 pm,
In vitro studies. The in vitro effects of S n -~r o t o~o r p h~r i n on were purchased from Schleicher and Schuell Inc. (Keene, NH). the ~~~u n o c h e m i c a l properties of brain mkr~somal HO-2 were All chemicals were of the highest purity commercially available. investigated by incubating brain microsomes with Sn-protoporThe animal experimentation described in this study was per-~h~r i n (10 PM final concentration) at 37°C for 0, 5, 15, and 45 formed with the highest standards of humane care according to min before electrophoresis and Western blottingthe guidelines set forth by the National Institutes of Health.
Western blot analysis. Protein samples were fractionated by Animal and tissue preparation. Adult male Sprague-Dawley SDS-PAGE (47) in 1.5-mm slab gels and were subsequently rats (1 75-225 g) were obtained from Harlan Industries (Madison, transferred to nitrocellulose membranes according to the method WI) and were given access to water and food ad libitum. Rats of Towbin et al. (48) , using an LKB Trans~hor Electroblotting were injected with a 25.0 mM solution of either Sn-or Zn-Cell. The method used for immunostaining has been described protoporphyrin (50.0 pmol/kg, i.v.) via tail vein and were killed previously (23) . hrified HO-1 (50 HO-2 (150 ~g ) , and either 6 h or 24 h later. Control animals received a comparable NADPH-cflochrome P-450 reductase (50 ~g ) were used as standamount of saline. The stock 25.0 mM metalloprotoporphyrin ards. Density of bands was quantified using an Ultra Scan XL solutions were prepared as described previously (2 1). Briefly, the densitometer. Densitometric quantifications were linear with metalloprotoporphyrins were dissolved in a minimum volume respect to the m~o u n t of protein hided. The Western and of 0.1 N NaOH and 95% ethanol and were thereupon diluted to Northern blots displayed represent two to four determinations 25.0 mM by the addition of 0.9% (wt/vol) NaC1. The pH was with one rat Per determination. adjusted to 7.2-7.4 by the addition of 1.0 N NaOH. ManipulaData U~U~Y S~S . Statistical analysis Was performed using t test; tions involving metalloprotoporphyrins were performed under a value ofp 5 0.05 was regarded as significant. Data are presented conditions of subdued lighting. Upon completion of the treat-as the mean SD. ment period, the animals were decapitated and the brains were used for the preparation of subcellular fractions, or they were RESULTS frozen in a dry-ice-ethanol bath and placed at -80°C until used for mRNA isolation. Brains were homogenized in ten tissue
The comparative effects of Sn-and Zn-protoporphyrin on volumes of 10.0 mM Tris-KC1 buffer, pH 7.4, containing 0.25 brain heme oxygenase activity were investigated, and the results M sucrose, and the microsomal and mitochondria1 fractions are depicted in Figure 1 . For this experiment, rats were treated were thereupon prepared as previously described (36) .
with either Sn-or Zn-protoporphyrin (50 pmol/kg, i.v.) and were
Purification of enzymes and antibody preparations. Purifica-killed 6 h later. As shown, Sn-protoporphyrin had a marked tion of rat liver HO-1, testes HO-2, liver NADPH-cytochrome inhibitory effect on heme oxygenase activity, resulting in nearly P-450 reductase, and liver biliverdin reductase was carried out negligible activity when compared with that of the controls. In as previously described (22, 23, 37 , and 38, respectively). The contrast, in Zn-protoporphyrin-treated rats no alteration of heme HO-1, HO-2, and NADPH-cytochrome P-450 reductase enzyme oxygenase activity in the brain was detected. preparations were used to raise antibody in New Zealand White Oxidation of heme requires the concerted activity of NADPHrabbits as previously detailed (39) .
cytochrome P-450 reductase along with heme oxygenase isoProbes, RNA preparation, and Northern blot analysis. The zymes; therefore, the possibility that the observed decrease in HO-2 probe used was the full-length (1300-bp) HO-2 cDNA heme oxygenase activity by Sn-protoporphyrin treatment was purified from a rat testis cDNA library (25) . A previously de-caused by compromised NADPH-cytochrome P-450 reductase scribed (33) adaptation of the PCR technique (40) was used to activity in the brain was explored. This possibility was investigenerate a cDNA fragment corresponding to HO-1 nucleotides gated by measuring the heme oxygenase activity in the presence +71 to +833 as reported by Shibahara et al. (30) . HO-1, HO-2, of exogenously supplemented reductase as well as measuring the and mouse 0-actin cDNA probes (41) results are depicted in Table 1 . As shown, Sn-protoporphyrin did indeed exert a deleterious effect on NADPH-cytochrome P-450 reductase activity; microsomes obtained from the brains of rats treated with Sn-protoporphyrin displayed a 40% reduction in the reductase activity when compared with control activity. Supplementation with exogenous NADPH-cytochrome P-450 reductase of the heme oxygenase assay system containing the microsomal fraction from Sn-protoporphyrin-treated rats as the enzyme source resulted in higher activity than that noted in the a absence of supplementation (Fig. 1) . However, the activity remained substantially lower than that of the control. Zn-protoporphyrin exerted no significant effect on the activity of the reductase. We also examined effects of Sn-protoporphyrin treatment 24 h after injection; at this time the activity of heme oxygenase approached that of the control value; however, the reductase activity remained somewhat lower than that of the controls (13.70 + 0.44 versus 17.01 & 3.08 nmol/mg/min).
The possibility that the observed dissolution of brain heme oxygenase activity upon treatment with Sn-protoporphyrin did not reflect solely the inhibition of enzyme activity was investigated by examining the effect of Sn-protoporphyrin treatment on enzyme protein using Western immunoblot technique. In addition, the microsomal levels of HO-1 and NADPH-cytochrome P-450 reductase were also assessed by this technique. The results are presented in Figure 2 . In these experiments, rats were treated for 6 h or 24 h with Sn-protoporphyrin. The blot Fig. 2 . Western immunoblot analysis of microsomal content of HO-1, HO-2, and NADPH-cytochrome P-450 reductase in brain of Snprotoporphyrin-treated rats. Microsomal fractions were prepared from the brains of Sprague-Dawley rats treated with Sn-protoporphyrin as described in the legend to Figure 1 and killed either 6 or 24 h later. Western blot analysis of HO-1, HO-2, and NADPH-cytochrome P-450 reductase (CCR) was camed out as described in Materials and Methods. The blot was developed using rabbit antibody preparations to rat liver HO-1, rat testes HO-2, and rat liver NADPH-cytochrome P-450 reductase. Purified preparations of HO-1, HO-2, and NADPH-cytochrome P-450 reductase were used as standards. Lane 1, 50 ng of purified HO-I; lane 2, 150 ng of purified HO-2; lane 3, 50 ng of purified NADPHcytochrome P-450 reductase; lanes 4 and 5, control; lanes 6 and 7, 6 h Sn-protoporphyrin; and lanes 8 and 9, 24 h Sn-protoporphyrin. Lanes 4-9 each contained 2 15 pg of microsomal protein.
was developed using an antibody preparation to HO-1 (bottom panel), HO-2 (middle panel), and the reductase (top panel). As shown, HO-1 could not be visualized by Western immunoblotting (bottom panel) under control or Sn-protoporphyrin-treated conditions, an observation that is consistent with our previous reports (28, 29) . In contrast, HO-2 and NADPH-cytochrome P-450 reductase were readily visualized. In microsomal fraction obtained from the brain of rats treated with Sn-protoporphyrin for 6 h (lanes 6 and 7), both HO-2 and the reductase were quantitatively diminished. Indeed, the detectable level of NADPH-cytochrome P-450 reductase protein was decreased by 32.7 + 6.8% (n = 4) when compared with control levels. As also noted, both the electrophoretic behavior and the level of HO-2 in the brain microsomes from 6-h Sn-protoporphyrin-treated rats differed from those of the control or 24-h Sn-protoporphyrintreated animals; the protein appeared as a wide and diffuse band and its level was reduced by 21% when compared with the control. HO-2 and NADPH-cytochrome P-450 reductase levels in protein samples obtained from 24-h Sn-protoporphyrintreated rats (lanes 8 and 9) were comparable to those of the controls. Treatment of rats with Zn-protoporphyrin for 6 h did not alter either the level or quality of HO-2, as seen in Figure 3 .
The possibility that Sn-protoporphyrin was interfering with the immunochemical properties of HO-2 and rendering it less readily detectable by immunoblotting was investigated, and the results are shown in Figure 4 . Before fractionation and immunoblotting, Sn-protoporphyrin (10 pM final concentration) was incubated with 150-pg protein samples of control brain microsomes at 37°C for 0, 5, 15, and 45 min (lanes 2-5, respectively). As shown, the metalloporphyrin did not appear to alter the immunochemical properties of HO-2.
In the subsequent experiment, we examined the possibility that Sn-protoporphyrin may exert deleterious effects on HO-2 transcripts (1.3 and 1.9 kb) in the brain, which were subsequently reflected in decreased protein levels. For comparison, Northern blot analysis of brain HO-1 mRNA (1.8 kb) was also canied out. As shown in Figure 5 , Northern blot analysis revealed that no changes occurred in either the single HO-1 mRNA (middle panel) or the two HO-2 mRNA levels (top panel) when poly(A)+ RNA was analyzed from rats treated 6 h and 24 h with Snprotoporphyrin (lanes 3 and 4 and 5 and 6, respectively). Also, the ratio of the two HO-2 transcripts did not change. These findings suggest that in the brain Sn-protoporphyrin exerts its effects, for the most part, at the protein level and suggest further the possibility that regulatory mechanisms for HO-1 and HO-2 in the brain are refractory to the metalloporphyrin. The absence of an increase in HO-1 mRNA in brain is rather intriguing insofar that this isozyme is induced in the liver by Sn-protoporphyrin treatment (49) .
Fig. 4. Effect in vitro o f Sn-protoporphyrin on the immunochemical properties o f HO-2 as assessed by Western immunoblotting. One hundred fifty-pg samples o f control brain microsomal protein were incubated at

DISCUSSION
Recently, the potential clinical use of Sn-protoporphyrin to suppress metabolic disorders of bilirubin metabolism such as Gilbert's syndrome in adults and postparturition hyperbilirubinemia in infants has been deemed as an attractive alternative to customary methods of treatment such as phototherapy and administration of barbiturates (9-1 1) . The promise of utility of the metalloporphyrin in clinical settings has been based on the premise that the complex is a specific competitive inhibitor of heme oxygenase and rather innocuous in nature. However, earlier inhibition studies were conducted in the absence of the knowledge of the existence of HO-2, the highly labile and noninducible form of heme oxygenase (22, 23) . The assumption of safety finds its foundation in studies that investigated a narrow range of biotransformation activities in the kidney and liver and some hematologic parameters in experimental animals (7, 50-52), wherein Sn-protoporphyrin reportedly did not appear to alter the assessed parameters to a discernible degree. In these 
.). Poly(A)+ RNA was isolated and Northern blot analyses were performed as described in Materials and Methods. A full-length 32P-labeled HO-2 cDNA was used as the hybridization probe for HO-2 m R N A (top panels), and a 32P-labeled HO-1 cDNA fragment was used to probe for HO-1 m R N A (middle panel). The same blot was subsequently probed with a-actin (bottom panel).
Each lane contained 4 studies, in both rats and mice, acute treatment with large quantities of Sn-protoporphyrin (100 pmol/kg/d for 5 d) or long-term (8-32 wk) administration of the complex were found rather innocuous (5 1, 52) .
The ability to assess the effect of the metalloporphyrin on HO-2 has only recently become feasible.,The present study took advantage of the recent availability of a cDNA probe (24) as well as primary antibody to HO-2 (23) to explore the effects of Snprotoporphyrin treatment on this isozyme in the brain. Under normal conditions, HO-2 accounts for nearly all heme oxygenase activity detected in the brain (28) . As noted in Figure 1 , the extent of inhibition of bilirubin formation in this organ was most striking, wherein the activity was nearly negligible 6 h after treatment. Sn-protoporphyrin has been previously reported to be detectable in the brain, albeit at low levels, 4 h after injection of the complex to adult rats (34) . It is, however, cleared from this organ very rapidly when compared with other tissues. Indeed, Anderson et al. (34) have noted that 12 h after Sn-protoporphyrin injection the complex is no longer detectable in the brain, whereas its levels are maintained in other organs such as kidney and liver. The rapid clearance of the complex is consistent with the presently observed return toward normal of the activity and protein levels of HO-2 24 h after Sn-protoporphyrin injection (Fig. 2) . It would appear that without the direct effect of Snprotoporphyrin, normal turnover of the noninducible isozyme as well as static levels of its transcripts would permit the activity and protein levels to return to normal.
When in the brain, aside from its known competitive inhibition of heme oxygenase activity (7, 8) , a number of other actions of Sn-protoporphyrin could account for the diminution of heme oxygenase activity. These are elaborated upon and discussed in the following. Recent studies with purified HO-1 and HO-2 suggest that the latter is more susceptible to inhibition by Snprotoporphyrin than HO-1 (53) . It follows that the brain, where virtually all heme oxygenase is HO-2, would be predicted to be especially susceptible to Sn-protoporphyrin-mediated inhibition. However, considering that Sn-protoporphyrin has been shown to promote photosensitization of bilirubin as well as its degradation (16-1 8) , the presently observed virtual depletion of measurable amounts of bilirubin in the heme oxygenase assay system containing microsomes from rats treated with Sn-protoporphyrin ( Fig. 1) could, in part, reflect such a phenomenon.
The observed decrease in HO-2 protein in the brain is an unpredicted observation and (Fig. 2) most likely contributes in a major way to the observed decreases in bilirubin production in assay system containing brain microsomes from Sn-protoporphyrin-treated rats. The in vitro experiment (Fig. 4) , which was designed to examine whether the metalloporphyrin had somehow compromised the immunochemical properties of brain microsoma1 HO-2, suggests that both the decrease in protein and loss of its integrity were indeed phenomena that occurred in vivo. It is noteworthy that Zn-protoporphyrin had no detectable effects on heme oxygenase isozymes in the brain, neither at the level of activity nor at the protein level (Figs. 1 and 3) . Sn-protoporphyrin has been shown to cross the blood-brain barrier in adult and neonatal rats (34, 35) . Such information, however, is not available for Zn-protoporphyrin. In the absence of such information, the lack of an effect by Zn-protoporphyrin on brain heme oxygenase may reflect the possibility that the zinc complex may not gain entry into the brain and thus is not capable of interacting with brain heme oxygenase isozymes. Alternatively, the lack of Zn-protoporphyrin-mediated effects on the isozymes may be the reflection of differences in kinetic and biochemical aspects of the interaction of the metalloporphyrin with brain heme oxygenase when compared with those of Sn-protoporphyrin.
The oxidation of heme requires the concerted activity of both heme oxygenase and NADPH-cytochrome P-450 reductase. As shown in Table 1 and Figure 2 , Sn-protoporphyrin clearly exerts deleterious effects upon both the activity and the level of the reductase protein in the brain. Because Sn-protoporphyrin has not been previously shown to competitively inhibit the reductase activity, it may be surmised that the observed decrease in NADPH-cytochrome P-450 reductase activity (Table 1) reflects primarily a decrease in the tissue level of the ~rotein (Fig. 2 ).
--, interestingly, upon supplementation of the hemeoxygenase assay svstem with the reductase. the relative extent of de~ression of &me oxygenase activity was lessened but was still highly pronounced (Table 1) . Specifically, as shown in Figure 1 , when heme oxygenase activity was measured in brain microsomes from rats treated 6 h with Sn-protoporphyrin in an assay system void of exogenous reductase, the activity was decreased to a mere fraction of the control; when the assay was supplemented with reductase, the activity rose to 24% of control levels. These observations suggest that the decrease in heme oxygenase activity is due in part to a decrease in the activity of NADPH-cytochrome P-450 reductase. It is noteworthy that the brain is capable of cytochrome P-450-mediated drug metabolism (54) for which the concerted activity of NADPH-cytochrome P-450 reductase is needed. Thus, decreased reductase activity could feasibly alter the capacity of the brain to cany out such biotransformations.
Our examination of transcripts for HO-1 and HO-2 in the brain revealed that the observed decrease in heme oxygenase is not due to alterations in the levels of the mRNA, or, in the case of HO-2, a change in the ratio of the two transcripts (Fig. 5) . Therefore, the reported potent photosensitizing activity of Snprotoporphyrin and its ability to generate free oxygen radicals (16, 17, 20) lead us to suspect that loss of the functional HO-2 and NADPH-cytochrome P-450 reductase protein in the brain may be related to the formation and activity of such free radicals. This may be of particular importance when one considers that low levels of antioxidants, such as glutathione (55, 56) , in the brain may render this organ somewhat less equipped than others to defend against free radical-mediated injury.
Neonatal jaundice can become of major clinical concern in some instances, and, because the customary modes of treatment (phototherapy, barbiturates, and transfusions) have potential drawbacks, alternative methods have been continuously sought. Sn-protoporphyrin is the only metalloporphyrin that has been used experimentally in humans, including neonates (l0,49). The results presented here, including the nonspecific deleterious effects of the complex on endoplasmic reticulum constituents, however, are disconcerting and warrant caution for its therapeutic use. In addition, cytochrome P-450-dependent steroid metabolism in the brain has only recently become actively researched (57, 58) . In light of the fact that Sn-protoporphyrin has been shown to decrease steroidogenesis in rat adrenals and testes (2 I), it appears reasonable to predict that steroid metabolism may also undergo alterations in brain of Sn-protoporphyrin-treated neonates. This is particularly alarming when one considers the regulatory role steroids play during development. For these reasons, if metalloporphyrin therapy as a treatment for neonatal jaundice continues to grow, we suggest that Zn-protoporphyrin is the agent of choice.
